Allouche Cyril 4
4 · Revance Therapeutics, Inc. · Filed Jul 3, 2018
Insider Transaction Report
Form 4
Allouche Cyril
Principal Financial Officer
Transactions
- Other
Common Stock
2018-06-29$23.33/sh+393$9,170→ 5,143 total
Footnotes (1)
- [F1]These shares were acquired by Mr. Allouche under the Issuer's 2014 Employee Stock Purchase Plan on June 29, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).